Finalists revealed for the Young Person of the Year at Pride of Cumbria Awards 2025
The event will be held on Wednesday, June 18 at the Greenhill Hotel, Wigton.
The finalists are:
Lilly Mae Grimes
Lilly Mae Grimes (Image: Supplied)
The 11 year old from Barrow in Furness has had a tough few years losing two grandads and her biological father all within 12 months, before finding out that her stepdad had been diagnosed with terminal cancer.
Lilly started counselling with cancer care and decided that she wanted to give back and so started making beaded pens and selling them with the proceeds being split between Cancer Care and Christie's Hospital in Manchester. So far she has raised over £1,000.
Her nominator said: "Lilly Mae has just received a large order for 200 keyrings so will make her total raised to over £1,500. She has a heart of gold and will do anything for anyone. She juggles all of this around school and helping care for her step father who is on palliative end of life care."
Bailey White
Bailey White (Image: Supplied) The six year old from Dearham was diagnosed with Type 1 Diabetes in June 2025 at five years old. Since his diagnosis he has shared his story with friends in class, his teachers, family and even strangers.
Bailey has worked really hard to fundraise money to buy books for newly diagnosed children and helped with his schools diabetes day where he made a 'hypo' kit for every child and a leaflet to spread awareness within the community.
His nominator said: "I feel for a six year old to have achieved such amazing things and to help families with young children going through a life long auto-immune disease is just outstanding."
Izzy and Summer Tinkler, Mia Hughes and Layla Harris
Izzy, Summer, Mia and Layla (Image: Supplied) The group of youngsters from Maryport, worked tirelessly during their February half term holidays to make and sell items on their charity stall, aiming to raise money for two charities in memory of Sadie Reed from the town who died at the age of 14.
Their nominator said: "I feel the girls should be awarded for their act of kindness, persistence and compassion to help those who are in terrible suffering."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection Six-Month Patient Follow-up Results Presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions Further Demonstrate that Sana's HIP-Modified Pancreatic Islet Cells are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Sana Is Incorporating its HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose with No Insulin and No Immunosuppression Recent FDA INTERACT Meeting Increases Confidence in Moving Forward with GMP Master Cell Bank for SC451 and in Filing SC451 Investigational New Drug Application (IND) as Early as 2026 Sana Expects Study Data to Be Generalizable across Multiple Cell Types and Patient Populations SEATTLE, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the New England Journal of Medicine (NEJM) has published a journal article titled 'Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression' (DOI: 10.1056/NEJMoa2503822). The article discusses 12-week results from an investigator-sponsored trial, conducted at Uppsala University Hospital, evaluating the transplantation of UP421, a primary human pancreatic islet cell therapy engineered with Sana's hypoimmune (HIP) technology, without the use of immunosuppressive medications in a 42-year-old patient living with type 1 diabetes for over three decades. The intramuscular transplantation of HIP-modified pancreatic islet cells is safe and well-tolerated and demonstrates that these cells evade autoimmune and allogeneic immune recognition, persist, and secrete insulin in a glucose-dependent manner over the 12-week evaluation period reported in the article. 12-week PET-MRI scanning also confirmed islet cells at the transplant site. Six-month data, described below, were recently presented at the ADA meeting and presented today at the World Transplant Congress 2025 concurrently with the publication of the NEJM article. 'We are thrilled to have the results of this study, which we believe represent both a scientific and medical breakthrough, recognized in the New England Journal of Medicine,' said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. 'Type 1 diabetes is a disease in which the immune system destroys the beta cells in pancreatic islets, requiring the patient to receive lifelong insulin therapy to control glucose levels. Although it is well established that pancreatic islet cell transplantation at a target therapeutic dose can predictably allow patients with type 1 diabetes to live without insulin therapy, until now these patients must take lifelong, significant immunosuppression, which is frequently toxic and difficult to tolerate. This study shows that Sana's novel HIP-modified pancreatic islets restore insulin production without the need for immunosuppression, a transformative outcome and significant step toward a broadly accessible, functional cure for patients with type 1 diabetes. The patient is making his own insulin for the first time in over 35 years.' 'These peer-reviewed results, built upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana, reinforce our belief that Sana has the capability to develop a functional cure for the broad population of individuals living with type 1 diabetes,' said Steve Harr, MD, Sana's President and Chief Executive Officer. 'The data, together with recent FDA feedback regarding our HIP-edited master cell bank for GMP manufacturing and our non-clinical testing plan for SC451, increase our confidence in our goal for treating type 1 diabetes—a single treatment with no immunosuppression that leads to long-term normal blood glucose without exogeneous insulin. We expect to file an IND for SC451, a next generation HIP-modified, stem cell-derived pancreatic islet therapy, as early as 2026 and begin Phase 1 testing shortly thereafter. I want to thank the entire Sana team, the investigators at Uppsala, and the patient who volunteered for this transformative, first-in-human study.' James Shapiro, M.D., Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta and leader of the clinical team that developed the Edmonton Protocol for islet cell transplantation, added 'Exogenous insulin therapy remains a lifesaving therapy in the short term, but it falls short of replicating the precise and dynamic glucose regulation of a healthy pancreas, leaving patients susceptible to both short- and long-term medical complications. This limitation motivated my team and me to pioneer a protocol for islet cell transplantation with immunosuppression and to continue innovating in this field. The data presented in the NEJM article—demonstrating that transplanted, engineered islet cells can both evade immune-mediated destruction and respond appropriately to insulin demands—represent a significant advancement in the ongoing pursuit of a definitive cure for type 1 diabetes and support my long-held belief that the future of type 1 diabetes treatment is in stem cell-based therapies.' Key Findings from Ongoing Study No serious adverse events or adverse events possibly or probably related to UP421 were identified in the study. HIP-modified pancreatic islet cells, transplanted with no immunosuppressive medicines, including no glucocorticoids, evade immune detection and rejection. Pancreatic islet cells survive and function post-transplantation. The survival and function of the HIP-modified pancreatic beta cells was confirmed at each blood draw, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels increase during monthly mixed meal tolerance tests (MMTT), showing increased insulin secretion in response to a meal. Of note, prior to transplant, the patient had undetectable C-peptide both when fasting and during an MMTT. MRI scans at each month show a sustained and consistent signal at the site of cell transplantation, consistent with graft survival. A PET-MRI scan with a tracer targeting pancreatic beta cells confirms that the surviving cells are, in fact, pancreatic beta cells. Sign in to access your portfolio
Medscape
6 days ago
- Medscape
Experts Advise on How to Study DEI in Cancer
As the largest financial supporter of medical research in the US, the National Institutes of Health (NIH) has helped uncover health disparities in cancer incidence, prevalence, and outcomes. Grants funded with that federal money aimed at reducing disparities have also included initiatives that enhanced the health of all patients with cancer. An example of these in the ACCURE study — Accountability for Cancer Care Through Undoing Racism and Equity — a system-based intervention to reduce Black-White disparities in treating early stage lung cancer that's now featured on the HDPulse site as one of the 23 interventions that improves minority health. Not only does that intervention resolve disparities between Black and White patients but 'it actually also shows markedly improved care for everyone,' said principal investigator Sam Cykert, MD, professor emeritus of The University of North Carolina at Chapel Hill (UNC). But since January, an executive order by the Trump administration has prohibited nearly all funding related to diversity, equity, and inclusion (DEI). It's not possible to characterize how much of that funding was specific to DEI-related research, but a total of $1.8 billion in overall NIH funding has been terminated through early April. That includes $223,566,041 in grants at the National Institute on Minority Health and Health Disparities (NIMHD), representing 8.9% of its funding from the NIH, and equivalent to 29.6% of all its grant funding. The National Cancer Institute had 0.6% of its grants cancelled, a total of $180,774,481. In June, a federal judge struck down the directive against using NIH funding for DEI-related research, but the Trump administration is likely to appeal the decision. Medscape Medical News reached out to the US Health and Human Services (HHS) for more information on the grants and amount of money cancelled and whether the department leadership has concerns about the impact of cancelled funding on cancer outcomes for marginalized populations. An HHS spokesperson told Medscape Medical News through email that the department 'remains committed to advancing cancer research and other serious health conditions' but does not see DEI-related research as part of that commitment. 'Unfortunately, this work was previously funded under an inappropriate and ideologically-driven — rather than scientifically driven — DEI program under the Biden Administration,' the spokesperson wrote. 'In the future, these types of programs will be reviewed based on their scientific merit rather than on DEI criteria.' Experts, however, emphasized the importance of ongoing research in this area. So how can they continue this work that they say is integral to improving healthcare for all? Alternative Sources of Funding Clinicians acknowledged significant barriers to conducting DEI-related medical research, but they also provided a glimmer of hope. In interviews with Medscape Medical News , they gave suggestions for how to find funding in these uncertain times. Cykert, who is also program director emeritus of UNC's Program on Health and Clinical Informatics, spent more than 30 years studying health disparities in cancer. He pointed out that the American Cancer Society has always been a strong funder in this area. 'Health equity across the cancer continuum' is one of their research priority areas, and they can often be competitive with what the National Cancer Institute pays. But he acknowledged that private foundations cannot close the gap left by NIH funds no longer available. 'We're going to have to start looking at alternate funding sources, at foundations like the American Cancer Society, the Robert Wood Johnson Foundation, Susan G. Komen, and private donors that increasingly are giving funds for cancer research,' said Yolanda VanRiel, PhD, RN, the department chair of Nursing at North Carolina Central University and a part-time patient placement coordinator at First Health of the Carolinas-Moore Regional Hospital. 'There are philanthropic arms of health systems that people don't think about,' she said. 'Industry partners, especially those that are focused on community engagement and patient-centered outcomes, are also viable.' She also mentioned PCORI (the Patient-Centered Outcomes Research Institute), and the Oncology Nursing Foundation. In addition, the Michelson Medical Research Foundation gives awards that focus specifically on immunology, vaccines, and immunotherapy. 'You can [also] collaborate with community-based organizations, and that can also open doors to funding that's tied to local or regional health equity initiatives as well,' VanRiel said. These options have always been there, but people have generally tried for NIH's big pot, she said. 'I think a lot of the time, when you're in specialty areas, you know about these, but it's time to make everybody realize that you can come back to the American Cancer Society,' she continued. 'When a lot of people think of Susan G. Komen, they think about the walk or other things, but they give out grants too.' Don Dizon, MD, a professor of medicine at Brown University's Warren Alpert Medical School, director of the Pelvic Malignancies Program at Lifespan Cancer Institute, and head of Community Outreach and Engagement at Legorreta Cancer Center, Providence, Rhode Island, said he has several colleagues whose funding has been pulled. Dizon, whose research includes health disparities among LGBTQ populations and advocacy on behalf of sexual and gender minoritized communities, called for 'more leadership from the institutional side' and for industry to step up. 'I think this is where industry can flex its muscle and say, 'We truly believe that addressing disparities when it comes to clinical trials is an important endeavor to ensure community health,'' he said. Advice for Wording Grant Applications VanRiel, Dizon, and Cykert also offered their thoughts on how to word federal grant applications to increase the likelihood of getting approval within the expectations of updated federal guidelines. 'I would emphasize that I'm going to make care better and cheaper for everyone,' Cykert said. 'Then we'll do a subgroup analysis to see if we're missing anybody.' 'We have proven that when you do system-wide interventions that reduce disparities, you actually improve care for everybody because the care for White patients isn't perfect in this medical system either,' he noted. Dizon calls for researchers to focus on the existing data in disparities research. 'The way forward is not to focus on the idea of advancing diversity, advancing equity, advancing inclusiveness [in grant applications] but to put forward a rationale to identify and address the disparities that exist in healthcare,' he said. He also suggested researchers look closely at the language in federal requests for proposals, as well. 'Be very careful to mirror the language that they're using because I do think they still want to do work in improving health outcomes for populations,' Dizon said. VanRiel recommended writing grants focused on the social determinants of cancer outcomes or geographic disparities, such as individuals in the South who face access barriers. 'Our responsibility as researchers is to produce knowledge that improves care for all patients,' she said. There still may be funding from the NIMHD, but the future of that institute remains unclear since the proposed 2026 budget for HHS noted that the NIMHD will be eliminated. Do you have ideas on how to continue doing work to improve research and, ultimately, care for underserved communities? Share those ideas at news@ .
Associated Press
04-08-2025
- Associated Press
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection Six-Month Patient Follow-up Results Presented at the 85thAnnual American Diabetes Association (ADA) Scientific Sessions Further Demonstrate that Sana's HIP-Modified Pancreatic Islet Cells are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Sana Is Incorporating its HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose with No Insulin and No Immunosuppression Recent FDA INTERACT Meeting Increases Confidence in Moving Forward with GMP Master Cell Bank for SC451 and in Filing SC451 Investigational New Drug Application (IND) as Early as 2026 Sana Expects Study Data to Be Generalizable across Multiple Cell Types and Patient Populations SEATTLE, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the New England Journal of Medicine (NEJM) has published a journal article titled 'Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression' (DOI: 10.1056/NEJMoa2503822). The article discusses 12-week results from an investigator-sponsored trial, conducted at Uppsala University Hospital, evaluating the transplantation of UP421, a primary human pancreatic islet cell therapy engineered with Sana's hypoimmune (HIP) technology, without the use of immunosuppressive medications in a 42-year-old patient living with type 1 diabetes for over three decades. The intramuscular transplantation of HIP-modified pancreatic islet cells is safe and well-tolerated and demonstrates that these cells evade autoimmune and allogeneic immune recognition, persist, and secrete insulin in a glucose-dependent manner over the 12-week evaluation period reported in the article. 12-week PET-MRI scanning also confirmed islet cells at the transplant site. Six-month data, described below, were recently presented at the ADA meeting and presented today at the World Transplant Congress 2025 concurrently with the publication of the NEJM article. 'We are thrilled to have the results of this study, which we believe represent both a scientific and medical breakthrough, recognized in the New England Journal of Medicine,' said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. 'Type 1 diabetes is a disease in which the immune system destroys the beta cells in pancreatic islets, requiring the patient to receive lifelong insulin therapy to control glucose levels. Although it is well established that pancreatic islet cell transplantation at a target therapeutic dose can predictably allow patients with type 1 diabetes to live without insulin therapy, until now these patients must take lifelong, significant immunosuppression, which is frequently toxic and difficult to tolerate. This study shows that Sana's novel HIP-modified pancreatic islets restore insulin production without the need for immunosuppression, a transformative outcome and significant step toward a broadly accessible, functional cure for patients with type 1 diabetes. The patient is making his own insulin for the first time in over 35 years.' 'These peer-reviewed results, built upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana, reinforce our belief that Sana has the capability to develop a functional cure for the broad population of individuals living with type 1 diabetes,' said Steve Harr, MD, Sana's President and Chief Executive Officer. 'The data, together with recent FDA feedback regarding our HIP-edited master cell bank for GMP manufacturing and our non-clinical testing plan for SC451, increase our confidence in our goal for treating type 1 diabetes—a single treatment with no immunosuppression that leads to long-term normal blood glucose without exogeneous insulin. We expect to file an IND for SC451, a next generation HIP-modified, stem cell-derived pancreatic islet therapy, as early as 2026 and begin Phase 1 testing shortly thereafter. I want to thank the entire Sana team, the investigators at Uppsala, and the patient who volunteered for this transformative, first-in-human study.' James Shapiro, M.D., Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta and leader of the clinical team that developed the Edmonton Protocol for islet cell transplantation, added 'Exogenous insulin therapy remains a lifesaving therapy in the short term, but it falls short of replicating the precise and dynamic glucose regulation of a healthy pancreas, leaving patients susceptible to both short- and long-term medical complications. This limitation motivated my team and me to pioneer a protocol for islet cell transplantation with immunosuppression and to continue innovating in this field. The data presented in the NEJM article—demonstrating that transplanted, engineered islet cells can both evade immune-mediated destruction and respond appropriately to insulin demands—represent a significant advancement in the ongoing pursuit of a definitive cure for type 1 diabetes and support my long-held belief that the future of type 1 diabetes treatment is in stem cell-based therapies.' Key Findings from Ongoing Study About the Uppsala University Hospital Investigator-Sponsored Study of UP421 in Type 1 Diabetes The investigator-sponsored study of UP421 is supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust. The study evaluates whether HIP-engineered insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without need of simultaneous treatment with immunosuppressive medicines. To do this, UP421 is engineered using Sana's HIP platform at Oslo University Hospital. The study involves intramuscular surgical transplantation of primary, or donor-derived, HIP-engineered islet cells into the forearm of patients with type 1 diabetes. The primary objective of the study is to investigate the safety of UP421 transplantation in patients with type 1 diabetes, with secondary endpoints including cell survival, immune evasion, and C-peptide production. Circulating C-peptide is a measure of endogenous insulin production. This first-in-human study examines a low dose of HIP-modified primary islets to initially establish the safety and function of HIP-modified islets without immunosuppression and, as a result, is not intended to show improvement in glycemia and/or reduction in exogenous insulin administration. The 12-week results have been published in the New England Journal of Medicine, and six-month results were presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions meeting on June 23, 2025, as well as at the World Transplant Congress 2025 on August 4, 2025. Results of the study over six months after islet cell transplantation demonstrate the survival and function of pancreatic beta cells through the latest timepoint at month six, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase during an MMTT, consistent with insulin secretion in response to a meal. At baseline, the patient had undetectable C-peptide both fasting and during an MMTT. The HIP platform has achieved proof-of-concept in humans, showing evasion of immune recognition with the potential broad application for allogeneic transplantation without immunosuppression. About the Sana Biotechnology Hypoimmune (HIP) Platform Sana's HIP platform is designed to generate cells ex vivo that can evade the patient's immune system to enable the transplantation of allogeneic cells without the need for immunosuppression. We are applying the HIP technology to develop therapeutic candidates at scale, including pluripotent stem cells, which can then be differentiated into multiple cell types, including pancreatic islet cells, and donor-derived allogeneic CAR T cells. We and our collaborators have generated significant foundational intellectual property in the area. Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals demonstrate across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. Sana's most advanced programs using this platform include a stem cell-derived pancreatic islet cell program for type 1 diabetes, an allogeneic CAR T program for B-cell mediated autoimmune diseases, and an allogeneic CAR T program targeting CD22+ cancers. About Sana Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA and Bothell, WA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the Company's vision, progress, and business plans; expectations for its development programs, product candidates, and technology platforms, including its preclinical, clinical and regulatory development plans and timing expectations, including the timing of filing investigational new drug applications and beginning Phase 1 testing, the impact of the FDA INTERACT meeting and feedback and the ability to move forward with the Company's HIP-edited master cell bank for GMP manufacturing and non-clinical testing plan for SC451, and the potential ability of SC451 to be a one-time treatment for patients with type 1 diabetes with no immunosuppression and to achieve normal blood glucose without exogenous insulin; the potential impact and significance of data from preclinical and clinical studies of the Company's product candidates and technologies, including the UP421 study of islet cell transplantation without immunosuppression in type 1 diabetes ('Study'), including the potential ability to develop a broadly accessible, functional cure for the broad population of individuals living with type 1 diabetes, the potential of the Study data to be generalizable across multiple cell types and patient populations, and the potential implications for the Company's SC451 program; expectations with respect to the role of stem cell-based therapies in the future of type 1 diabetes treatment; the potential ability of the HIP platform to have broad application and to generate cells ex vivo that can evade the patient's immune system to enable the transplantation of allogeneic cells without the need for immunosuppression, and to be applied to develop therapeutic candidates at scale, including pluripotent stem cells, which can be differentiated into multiple cell types, and donor-derived allogeneic CAR T cells; the potential safety and survival, function, and immune evasion of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression; and statements made by Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital, statements made by the Company's President and CEO, and statements made by the Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's Securities and Exchange Commission (SEC) reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Investor Relations & Media: Nicole Keith [email protected] [email protected]
